Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Greenland Capital Management LP

Greenland Capital Management LP lifted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 958.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 105,853 shares of the company’s stock after purchasing an additional 95,853 shares during the period. Greenland Capital Management LP owned about 0.16% of Mineralys Therapeutics worth $4,014,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MLYS. Smartleaf Asset Management LLC boosted its stake in shares of Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after buying an additional 676 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after purchasing an additional 702 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Mineralys Therapeutics by 42.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Mineralys Therapeutics by 3.2% during the 3rd quarter. Rhumbline Advisers now owns 55,291 shares of the company’s stock worth $2,097,000 after purchasing an additional 1,695 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its position in shares of Mineralys Therapeutics by 29.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,234 shares of the company’s stock worth $125,000 after purchasing an additional 2,098 shares during the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MLYS has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. HC Wainwright increased their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus boosted their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $47.43.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $28.93 on Tuesday. The stock’s 50-day moving average is $32.86 and its two-hundred day moving average is $34.30. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $47.65. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -9.81 and a beta of 0.52.

Insider Buying and Selling

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $32.14, for a total transaction of $345,762.12. Following the transaction, the chief financial officer owned 8,638 shares of the company’s stock, valued at $277,625.32. The trade was a 55.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jon Congleton sold 16,236 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.62, for a total value of $529,618.32. Following the completion of the sale, the chief executive officer owned 639,151 shares of the company’s stock, valued at approximately $20,849,105.62. This represents a 2.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 340,748 shares of company stock worth $11,697,169 in the last quarter. 33.24% of the stock is owned by insiders.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.